BioVaxys Technology Statistics
BioVaxys Technology (5LB0) Stock Statistics & Valuation Metrics
Total Valuation
BioVaxys Technology has a market cap or net worth of EUR 1.30M. The enterprise value is EUR 5.96M.
- Market Cap
- EUR 1.30M
- Enterprise Value
- EUR 5.96M
Share Statistics
BioVaxys Technology has 44,094,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 44,094,670
- Owned by Insiders
- 8.08%
- Owned by Institutions
- ―
Financial Efficiency
BioVaxys Technology’s return on equity (ROE) is 2.06 and return on invested capital (ROIC) is 177.94%.
- Return on Equity (ROE)
- 2.06
- Return on Assets (ROA)
- -3.04
- Return on Invested Capital (ROIC)
- 177.94%
- Return on Capital Employed (ROCE)
- 1.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.32M
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BioVaxys Technology is -0.35. BioVaxys Technology’s PEG ratio is 0.02.
- PE Ratio
- -0.35
- PS Ratio
- 0.00
- PB Ratio
- -0.71
- Price to FCF
- -0.70
- Price to Operating Cash Flow
- -0.74
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, BioVaxys Technology had revenue of 0 and earned -3.95M in profits. Earnings per share was -0.20.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.30M
- Pretax Income
- -3.95M
- Net Income
- -3.95M
- EBITDA
- -3.95M
- Earnings Per Share (EPS)
- -0.20
Cash Flow
In the last 12 months, operating cash flow was -2.97M and capital expenditures -4, giving a free cash flow of -2.97M billion.
- Operating Cash Flow
- -2.97M
- Free Cash Flow
- -2.97M
- Free Cash Flow per Share
- -0.15
Dividends & Yields
BioVaxys Technology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -143.02%
- Earnings Yield
- -288.66%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -79.72%
- 50-Day Moving Average
- 0.03
- 200-Day Moving Average
- 0.03
- Relative Strength Index (RSI)
- 49.14
- Average Volume (3m)
- ―
Important Dates
BioVaxys Technology upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 25, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
BioVaxys Technology as a current ratio of 0.40, with Debt / Equity ratio of -3.55%
- Current Ratio
- 0.40
- Quick Ratio
- 0.40
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BioVaxys Technology has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioVaxys Technology EV to EBITDA ratio is -0.48, with an EV/FCF ratio of -0.65.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.48
- EV to Free Cash Flow
- -0.65
- EV to Operating Cash Flow
- -1.02
Balance Sheet
BioVaxys Technology has EUR 4,080.00 in cash and marketable securities with EUR 133.72K in debt, giving a net cash position of -EUR 129.64K billion.
- Cash & Marketable Securities
- EUR 4,080.00
- Total Debt
- EUR 133.72K
- Net Cash
- -EUR 129.64K
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- -EUR 0.12
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
